After decades of legal medical cannabis, and recent adult-use legalization, we are still nowhere near medical cannabis reform in Canada. But hope is not lost.
Author: Ashley Keenan
Ashley Keenan is a writer and medical cannabis advocate who uses reporting and storytelling to destigmatize the plant. Ashley loves to educate and entertain with her work; covering all things cannabis from industry news to health and beauty.
Cannabis businesses continue to face barriers with Canadian banks
It appears as though Canadian banks missed the memo on cannabis legalization in 2018. Numerous cannabis-based businesses have expressed difficulty applying for and maintaining bank
Global cannabis survey aims to provide insight on cannabis cultivation and drive international policy reform
A survey asking questions about cannabis cultivation is getting a tepid response from the cannabis community and lagging in Canadian respondents. The survey is run
Yes, cannabis patients want (and deserve) pre-rolls
A number of medical providers have started to offer pre-rolled joints in addition to dried flower by the gram, raising questions on the validity of
That’s a solid ‘meh’ from me on cannabis 2.0 beverages
The early days of cannabis 2.0 were met with a tepid response from the industry as ‘no one wants beverages’ echoed through the Twitterverse. Health
How will changes to cannabis oil regulations impact patients?
Medicating with cannabis oil products might soon become slightly less convenient for patients, especially those on high dose THC or CBD treatment plans. Cannabis oil
Superette joins Broccoli Magazine’s anti-racism initiative the Floret Coalition
Canadian cannabis retailer Superette announced its pledge to join the Floret Coalition, an initiative to support and fund BIPOC enterprises within the cannabis industry.
The untapped potential of cannabis topicals
It has been six months since ‘cannabis 2.0’ brought a wave of new cannabis products to the Canadian market. New items like beverages, edibles, and concentrates were greenlit for production and sale last October, hitting shelves mid-to-late December pending a 60-day approval period.
